Researchers Discover Potential Treatment for Genetic Hearing Loss Using Arginine and Sildenafil

Researchers have identified a promising approach to potentially reverse certain types of genetic hearing loss, according to a groundbreaking new study. The research focuses on hearing impairment caused by mutations in a specific gene present at birth, which might be treatable using a combination of a common dietary supplement and sildenafil, the active ingredient in Viagra.

The study centered on mutations in the CPD gene, which produces an enzyme called carboxypeptidase D. Researchers identified these mutations in three unrelated families from Turkey where multiple members were born deaf. All affected individuals had inherited sensorineural hearing loss, a condition caused by damage to the tiny hair cells in the inner ear that convert sound vibrations into electrical signals for the brain.

“We subsequently found that CPD mutations are present in people with hearing loss in a large genome sequencing cohort from England,” explained study author Dr. Mustafa Tekin, professor and chair of the Department of Human Genetics at University of Miami Miller School of Medicine.

To better understand the connection, the research team compared genetic data between affected and unaffected family members, then expanded their analysis to other populations.

Laboratory experiments revealed crucial insights into the underlying mechanism. When researchers deactivated the CPD gene in human cells, they observed reduced levels of three critical substances: arginine (an amino acid), cyclic guanosine monophosphate (cGMP, an important signaling molecule), and nitric oxide, which provides vital signals to the nervous system.

The research then moved to animal models to further investigate the findings. In mice, when nitric oxide and cGMP levels dropped, hair cells in the inner ear became overstressed and eventually died. Similarly, in fruit flies, silencing the equivalent of the CPD gene led to defects in organs responsible for detecting sound and maintaining balance.

The breakthrough came when researchers administered arginine to human cells, which restored nitric oxide to normal levels and reduced cell death. Additionally, they discovered that sildenafil, which acts on the nitric oxide pathway, reversed some deficits caused by CPD mutations.

“Nitric oxide is vital for many tissues and must be kept in a fine balance,” Tekin noted.

These findings suggest that nitric oxide deficiency in the cochlea—the inner ear structure that converts sound vibrations to nerve signals—may be a primary driver of this type of hearing loss. The CPD gene appears to regulate this process by maintaining proper arginine and nitric oxide levels in hair cells, which are essential for healthy signal transmission and protection against damage.

Despite the promising results, the research team emphasized they are not proposing sildenafil as a hearing loss treatment for general use. “We used it to strengthen the argument that nitric oxide deficiency in the ear was the underlying cause of deafness,” Tekin clarified.

Medical experts not involved in the study urge extreme caution regarding any premature applications. Dr. Nooshin Parhizkar, an ENT physician practicing in the San Francisco Bay Area, highlighted that sildenafil has been associated with rare but serious cases of sudden hearing loss and irreversible tinnitus.

“At this stage, it is not appropriate or safe for the general public to use Viagra for hearing issues,” she warned.

The Food and Drug Administration has already added warning labels to sildenafil and other PDE5 inhibitors about the potential risk of sudden hearing loss following rare reports among users. Though typically temporary and reversible after discontinuing the medication, the exact causality remains unclear, as affected patients may have had other medical conditions or been taking additional medications.

The study has important limitations. It focused on a very specific, genetically defined group of patients, so findings likely won’t apply to most people with hearing loss. Additionally, since much of the reversal research was conducted in mice and fruit flies, human trials would be necessary before any clinical applications could be considered.

“It is important to get a genetic test done to find the cause of hearing loss,” Tekin advised. While scientists have identified more than 200 genes linked to hearing impairment, commercial genetic screening tests often focus only on the most common mutations.

This research represents a significant step forward in understanding genetic hearing loss mechanisms and offers hope for future targeted treatments for specific genetic forms of deafness.